| Stereochemistry | ABSOLUTE |
| Molecular Formula | C10H16N2O2 |
| Molecular Weight | 196.2462 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
O=C([C@H]1CCC(=O)N1)N2CCCCC2
InChI
InChIKey=GOWRRBABHQUJMX-MRVPVSSYSA-N
InChI=1S/C10H16N2O2/c13-9-5-4-8(11-9)10(14)12-6-2-1-3-7-12/h8H,1-7H2,(H,11,13)/t8-/m1/s1
| Molecular Formula | C10H16N2O2 |
| Molecular Weight | 196.2462 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Fasoracetam is a cognition enhancer that interacts with GABA(B) receptors, stimulates neuronal ACh receptors and modulates mGlu receptors. The drug is being tested in phase III/II of clinical trials for the treatment of Attention Deficit Disorder With Hyperactivity in people with genetic disorders impacting mGlu receptors and never been approved by FDA. Fasoracetam is also being marketed in the form of capsules for research purposes aimed at investigation of cognition and memory disorders.
CNS Activity
Originator
Approval Year
Cmax
AUC
T1/2
Doses
PubMed
Patents
Sample Use Guides
100, 200, or 400 mg twice daily as capsules for oral administration.
Route of Administration:
Oral
Fasoracetam (10(-7) and 10(-6) M) inhibited forskolin-stimulated cyclic AMP formation in cultured neurons of the mouse cerebral cortex. Conversely, in pertussis toxin-pretreated neurons, the drug (10(-7)-10(-5) M) significantly enhanced the forskolin-stimulated cyclic AMP formation, and this action was completely reversed by cholera toxin.
